The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Endogenous Cannabinoid Signaling
Open accessAbstract
There are two principal lines of evidence supporting the existence of an endogenous cannabinoid system. First, it is clear that cannabimimetic drugs exert their effects by binding with high affinity to selective membrane receptors (1–3). Second, substances with cannabimimetic properties, but with chemical structures that greatly differ from those found in plants, have been discovered in animal tissues (4–7). These indications are relevant, but they are open nevertheless to several possible objections. For example, although endogenous cannabimimetic compounds exist, it is conceivable that they may never engage cannabinoid receptors under physiological conditions. Indeed, if these receptors were constitutively active in the absence of agonist, as suggested by studies with heterologous expression models (8), there may be no need for an intrinsic cannabinoid ‘‘system,’’ intended as a group of interconnected cells that produce and respond to endogenous cannabinoids. These and similar concerns highlight the many gaps left unfilled in our understanding of intrinsic cannabinoid modulation. It is now generally agreed that substances with cannabimimetic properties are released during neuronal activity, and that these substances are inactivated by a set of mechanisms parallel to, but distinct from, those utilized for the elimination of established neurotransmitters. But where in brain and peripheral tissues do these reactions take place? And under what circumstances? Are there discrete cannabinergic pathways comparable to, say, dopaminergic ones? Or do endogenous cannabinoids act as local mediators? What behavioral needs regulate endogenous cannabinoid release?And what physiological adaptations are served by such release? To address these questions critically, we need first to recognize certain biochemical and physiological peculiarities of the cannabinoid signaling system which distinguish it from classical neurotransmitters. The nature of these peculiarities is the key theme that will be developed in the present review. ENDOGENOUS CANNABINOIDS
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular characterization of a peripheral receptor for cannabinoids
Munro, S., Thomas, K. L., & Abu-Shaar, M. (1993) · Nature · doi:10.1038/365061a0 · Cited by 5,092 · cited 1×
“The molecular identity of this putative receptor subtype is unknown, although it is likely to be distinct from the cloned CB2 receptor (3) for which palmitylethanolamide shows little or no binding affinity (32) (but see 33, for contrasting results).”
BackgroundStructure of a cannabinoid receptor and functional expression of the cloned cDNA
Matsuda, L. A., Lolait, S. J., Brownstein, M. J., Young, A. C., & Bonner, T. I. (1990) · Nature · doi:10.1038/346561a0 · Cited by 5,011
Mechoulam, R., Ben-Shabat, S., Hanus, L., Ligumsky, M., Kaminski, N. E., Schatz, A. R., Gopher, A., Almog, S., Martin, B. R., Compton, D. R., et al. (1995) · Biochemical Pharmacology · doi:10.1016/0006-2952(95)00109-d · Cited by 2,913
Determination and characterization of a cannabinoid receptor in rat brain
Devane, W. A., Dysarz, F. A., Johnson, M. R., Melvin, L. S., & Howlett, A. C. (1988) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)09876-1 · Cited by 2,443
Cannabinoid receptor localization in brain.
Herkenham, M., Lynn, A. B., Little, M. D., Johnson, M. R., Melvin, L. S., de Costa, B. R., & Rice, K. C. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.5.1932 · Cited by 2,321 · cited 1×
“7–2 μM (7,6,43), the levels of 2-AG found after stimulation are expected to cause a substantial activation of the dense CB1 receptor population expressed in hippocampus (45,46).”
Background2-Arachidonoylgylcerol: A Possible Endogenous Cannabinoid Receptor Ligand in Brain
Sugiura, T., Kondo, S., Sukagawa, A., Nakane, S., Shinoda, A., Itoh, K., Yamashita, A., & Waku, K. (1995) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1995.2437 · Cited by 2,196
Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides
Cravatt, B. F., Giang, D. K., Mayfield, S. P., Boger, D. L., Lerner, R. A., & Gilula, N. B. (1996) · Nature · doi:10.1038/384083a0 · Cited by 2,125 · cited 2×
“The intracellular localization of this enzyme, termed anandamide amidohydrolase or fatty acid amide hydrolase, is supported by studies with subcellular membrane fractions (61), by its deduced amino acid sequence (62), and by the fact that anandamide hydrolysis takes place after this lipid has been accumulated in cells…”
BackgroundImmunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system
Tsou, K., Brown, S., Sañudo-Peña, M. C., Mackie, K., & Walker, J. M. (1998) · Neuroscience · doi:10.1016/s0306-4522(97)00436-3 · Cited by 1,586
Facci, L., Dal Toso, R., Romanello, S., Buriani, A., Skaper, S. D., & Leon, A. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.8.3376 · Cited by 632
Anandamide Amidohydrolase Activity in Rat Brain Microsomes
Desarnaud, F., Cadas, H., & Piomelli, D. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.11.6030 · Cited by 336
Self-citation
Cited by
Endocannabinoid Signaling in the Brain
Wilson, R. I., & Nicoll, R. A. (2002) · Science · doi:10.1126/science.1063545 · Cited by 1,260
Marsicano, G., & Lutz, B. (1999) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.1999.00847.x · Cited by 937
Iversen, L. (2003) · Brain · doi:10.1093/brain/awg143 · Cited by 732
An anorexic lipid mediator regulated by feeding
Rodríguez de Fonseca, F., Navarro, M., Gómez, R., Escuredo, L., Nava, F., Fu, J., Murillo-Rodríguez, E., Giuffrida, A., LoVerme, J., Gaetani, S., et al. (2001) · Nature · doi:10.1038/35102582 · Cited by 694
Self-citationNonpsychotropic Cannabinoid Receptors Regulate Microglial Cell Migration
Walter, L., Franklin, A., Witting, A., Wade, C., Xie, Y., Kunos, G., Mackie, K., & Stella, N. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-04-01398.2003 · Cited by 665
Self-citationPresynaptic Specificity of Endocannabinoid Signaling in the Hippocampus
Wilson, R. I., Kunos, G., & Nicoll, R. A. (2001) · Neuron · doi:10.1016/s0896-6273(01)00372-5 · Cited by 544
The endocannabinoid system as a target for therapeutic drugs
Piomelli, D., Giuffrida, A., Calignano, A., & Rodrı́guez de Fonseca, F. (2000) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(00)01482-6 · Cited by 421
Self-citationTwo Coincidence Detectors for Spike Timing-Dependent Plasticity in Somatosensory Cortex
Bender, V. A., Bender, K. J., Brasier, D. J., & Feldman, D. E. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.0176-06.2006 · Cited by 381
Sugiura, T., Kobayashi, Y., Oka, S., & Waku, K. (2002) · Prostaglandins, Leukotrienes and Essential Fatty Acids (PLEFA) · doi:10.1054/plef.2001.0356 · Cited by 348
Cannabis and psychosis/schizophrenia: human studies
D’Souza, D. C., Sewell, R. A., & Ranganathan, M. (2009) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-009-0024-2 · Cited by 295
Manzanares, J., Julian, M., & Carrascosa, A. (2006) · Current Neuropharmacology · doi:10.2174/157015906778019527 · Cited by 287
“In addition, other compounds like the N-acylethanolamines block anandamide degradation [118].”
Tanda, G., & Goldberg, S. R. (2003) · Psychopharmacology · doi:10.1007/s00213-003-1485-z · Cited by 277
Cannabinoid Delivery Systems for Pain and Inflammation Treatment
Bruni, N., Della Pepa, C., Oliaro-Bosso, S., Pessione, E., Gastaldi, D., & Dosio, F. (2018) · Molecules · doi:10.3390/molecules23102478 · Cited by 272
Structural determinants for recognition and translocation by the anandamide transporter
Piomelli, D., Beltramo, M., Glasnapp, S., Lin, S. Y., Goutopoulos, A., Xie, X.-Q., & Makriyannis, A. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.10.5802 · Cited by 268
Self-citationActivation of TRPV1 by the Satiety Factor Oleoylethanolamide
Ahern, G. P. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m305051200 · Cited by 257
The insults of illicit drug use on male fertility
Fronczak, C. M., Kim, E. D., & Barqawi, A. B. (2012) · Journal of Andrology · doi:10.2164/jandrol.110.011874 · Cited by 217
Cannabinoid and opioid interactions: implications for opiate dependence and withdrawal
Scavone, J. L., Sterling, R. C., & Van Bockstaele, E. J. (2013) · Neuroscience · doi:10.1016/j.neuroscience.2013.04.034 · Cited by 209
Fatty Acid Amide Hydrolase: A Gate-Keeper of the Endocannabinoid System
Fezza, F., De Simone, C., Amadio, D., & Maccarrone, M. (2008) · Subcellular Biochemistry · doi:10.1007/978-1-4020-8831-5_4 · Cited by 99
Guindon, J., & Beaulieu, P. (2006) · Neuropharmacology · doi:10.1016/j.neuropharm.2005.12.002 · Cited by 90
Novel inhibitors of fatty acid amide hydrolase
Sit, S. Y., Conway, C., Bertekap, R., Xie, K., Bourin, C., Burris, K., & Deng, H. (2007) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2007.04.009 · Cited by 52
La Rana, G., Russo, R., D'Agostino, G., Sasso, O., Raso, G. M., Iacono, A., Meli, R., Piomelli, D., & Calignano, A. (2008) · Neuropharmacology · doi:10.1016/j.neuropharm.2007.10.021 · Cited by 42
“The endogenous acylethanolamides are a group of substances generated on demand through stimulus-dependent cleavage of membrane phospholipid precursors and, after their release, undergo a rapid inactivation (Di Marzo et al., 1994; Piomelli et al., 1998).”
BackgroundRodella, L. F., Borsani, E., Rezzani, R., Ricci, F., Buffoli, B., & Bianchi, R. (2005) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2004.12.031 · Cited by 32
Metadata
- Authors
- Piomelli, D., Beltramo, M., Giuffrida, A., & Stella, N.
- Venue
- Neurobiology of Disease
- Publisher
- Elsevier BV
- Published
- 1998-12
- Volume
- 5
- Issue
- 6
- Pages
- 462-473
- ISSN
- 0969-9961 (ISSN-L)
- OpenAlex
- W2023733270
- Cited by
- 159
- References
- 10
- FWCI
- 6.65
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.